Himisha Beltran, MD (Damon Runyon-Gordon Family Clinical Investigator ’13-’16) of Weill Cornell Medicine, New York, and colleagues, used next-generation sequencing technologies to analyze neuroendocrine prostate cancer, an aggressive resistant form of cancer which sometimes develops in certain patients. The researchers examined resistance in samples collected from 81 patients and discovered the distinctive genetic, epigenetic and molecular features that underlie neuroendocrine prostate cancer. Their findings may enable researchers to develop biomarkers to help identify this subset of patients with prostate cancer less likely to respond to the next line of hormonal-based therapies. In addition, this data may be used to develop new therapeutic approaches for patients. The study was published in the journal Nature Medicine.
